Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Laboratory Medicine, Radboudumc Graduate School, Radboud University Medical Center, Nijmegen, The Netherlands.
Eur J Endocrinol. 2023 Oct 17;189(4):460-468. doi: 10.1093/ejendo/lvad143.
Testicular adrenal rest tumors (TARTs), often found in male patients with congenital adrenal hyperplasia (CAH), are benign lesions causing testicular damage and infertility. We hypothesize that chronically elevated adrenocorticotropic hormone exposure during early life may promote TART development.
This study aimed to examine the association between commencing adequate glucocorticoid treatment early after birth and TART development.
This retrospective multicenter (n = 22) open cohort study collected longitudinal clinical and biochemical data of the first 4 years of life using the I-CAH registry and included 188 male patients (median age 13 years; interquartile range: 10-17) with 21-hydroxylase deficiency (n = 181) or 11-hydroxylase deficiency (n = 7). All patients underwent at least 1 testicular ultrasound.
TART was detected in 72 (38%) of the patients. Prevalence varied between centers. When adjusted for CAH phenotype, a delayed CAH diagnosis of >1 year, compared with a diagnosis within 1 month of life, was associated with a 2.6 times higher risk of TART diagnosis. TART onset was not predicted by biochemical disease control or bone age advancement in the first 4 years of life, but increased height standard deviation scores at the end of the 4-year study period were associated with a 27% higher risk of TART diagnosis.
A delayed CAH diagnosis of >1 year vs CAH diagnosis within 1 month after birth was associated with a higher risk of TART development, which may be attributed to poor disease control in early life.
睾丸肾上腺残余肿瘤(TART)常存在于患有先天性肾上腺增生症(CAH)的男性患者中,是引起睾丸损伤和不育的良性病变。我们假设,生命早期慢性升高的促肾上腺皮质激素暴露可能促进 TART 的发展。
本研究旨在研究出生后早期开始充分糖皮质激素治疗与 TART 发展之间的关联。
这是一项回顾性多中心(n=22)开放队列研究,使用 I-CAH 登记处收集了生命前 4 年的纵向临床和生化数据,包括 188 名男性患者(中位数年龄 13 岁;四分位间距:10-17),患有 21-羟化酶缺乏症(n=181)或 11-羟化酶缺乏症(n=7)。所有患者均至少进行了 1 次睾丸超声检查。
72 名(38%)患者检测到 TART。患病率在各中心之间存在差异。与出生后 1 个月内诊断相比,CAH 诊断延迟超过 1 年与 TART 诊断风险增加 2.6 倍相关。在生命的前 4 年中,TART 的发病未预测生化疾病控制或骨龄进展,但在 4 年研究期结束时身高标准差评分增加与 TART 诊断风险增加 27%相关。
与出生后 1 个月内诊断相比,CAH 诊断延迟超过 1 年与 TART 发展风险增加相关,这可能归因于生命早期疾病控制不佳。